Sugi Predict

Sugi Predict / Targets / Q6ZSR9

Q6ZSR9

Uncharacterized protein FLJ45252 · Q6ZSR9 · Q6ZSR9 on Sugi Atlas →

17,166 patent compounds predicted against Q6ZSR9, 14,102 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL98692 SCHEMBL98692 0.92 2/20
SCHEMBL100845 SCHEMBL100845 0.80 2/20
SCHEMBL100309 SCHEMBL100309 0.77 2/20
SCHEMBL101864 SCHEMBL101864 0.74 2/20
SCHEMBL101702 SCHEMBL101702 0.71 2/20
SCHEMBL99685 SCHEMBL99685 0.71 2/20
SCHEMBL100966 SCHEMBL100966 0.70 2/20
SCHEMBL101072 SCHEMBL101072 0.70 2/20
SCHEMBL101686 SCHEMBL101686 0.70 2/20
SCHEMBL103295 SCHEMBL103295 0.68 2/20
SCHEMBL100150 SCHEMBL100150 0.66 2/20
SCHEMBL101800 SCHEMBL101800 0.66 2/20
SCHEMBL102410 SCHEMBL102410 0.66 2/20
SCHEMBL99551 SCHEMBL99551 0.65 2/20
SCHEMBL99828 SCHEMBL99828 0.65 2/20
SCHEMBL100575 SCHEMBL100575 0.65 2/20
SCHEMBL100859 SCHEMBL100859 0.65 2/20
SCHEMBL98675 SCHEMBL98675 0.65 2/20
SCHEMBL103169 SCHEMBL103169 0.65 2/20
SCHEMBL101901 SCHEMBL101901 0.64 2/20

Clinical trials — most relevant to Q6ZSR9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment of Ectopic Calcification in Fahr's Disease or Syndrome PHASE2RECRUITING
The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV PHASE1COMPLETED
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS PHASE1UNKNOWN
Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB. PHASE1COMPLETED
The Effects of GLA on Human Volunteers PHASE1COMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH) nanCOMPLETED
Does Genetic Susceptibility for Bleeding Affect Quantitative Faecal Immunochemical Test (qFIT) Results? nanWITHDRAWN
Chromosome 9 P Minus Syndrome nanRECRUITING
Mechanisms of Inherited Retinal Dystrophies Using Whole Genome Sequencing and in Vitro and in Vivo Models nanCOMPLETED
Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions nanRECRUITING
Study of Constitutional Platelet Disease nanUNKNOWN
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
WGS of Korean Idiopathic Bronchiectasis nanUNKNOWN
Genetic Analysis of Fraser Syndrome and Fryns Syndrome nanCOMPLETED
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF) nanUNKNOWN
New Strategies of Genetic Study of Patients With Oculocutaneous Albinism nanCOMPLETED
Genomic Predictors of Recurrent Pregnancy Loss nanRECRUITING
Genetic Investigations in Children With Developmental and Epileptic Encephalopathies in Ho Chi Minh City, Vietnam nanUNKNOWN
Virulence Determinants in S Aureus Bacteremia nanCOMPLETED
The Role of Bacteria and Genetic Variations in Cystic Fibrosis nanCOMPLETED
Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy nanCOMPLETED
PCD New Gene Discovery nanCOMPLETED
Whole Genome Scan of Extended Families With Familial Vocal Cord Paralysis nanCOMPLETED
Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions nanCOMPLETED
Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder nanACTIVE_NOT_RECRUITING
Italian Anderson Fabry Disease Cardiovascular Registry nanRECRUITING
Lipodystrophy Connect Patient Registry nanCOMPLETED
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Gene Modifiers of Cystic Fibrosis Lung Disease nanACTIVE_NOT_RECRUITING
Identifying Genome Variants in Non-Obstructive Azoospermia (NOA) or Primary Ovarian Insufficiency (POI) nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a Q6ZSR9 binder may also engage these)

ProteinNameSimilarity
Q6PIU9 — 0.996 Q6PIU9 →
Q62394 — 0.995 Q62394 →
Q5DTX6 — 0.995 Q5DTX6 →
Q8BI29 — 0.995 Q8BI29 →
A6NGG8 — 0.993 A6NGG8 →
Q5H9B9 — 0.993 Q5H9B9 →
O46385 — 0.992 O46385 →
Q499V8 — 0.992 Q499V8 →
Q9Y6A5 — 0.992 Q9Y6A5 →
Q8R080 — 0.992 Q8R080 →
Q9NTX9 — 0.992 Q9NTX9 →
Q9BW04 — 0.992 Q9BW04 →
Q6NS69 — 0.992 Q6NS69 →
Q7TS75 — 0.991 Q7TS75 →
Q9H425 — 0.991 Q9H425 →
Q7TPM1 — 0.990 Q7TPM1 →
Q922B9 — 0.990 Q922B9 →
Q6GQV1 — 0.990 Q6GQV1 →
Q6ZVD7 — 0.990 Q6ZVD7 →
Q5VWP3 — 0.990 Q5VWP3 →
A6H5Y1 — 0.990 A6H5Y1 →
Q0VET5 — 0.990 Q0VET5 →
A2AHC3 — 0.990 A2AHC3 →
D3ZUI5 — 0.990 D3ZUI5 →
A5D7K1 — 0.990 A5D7K1 →
O88573 — 0.990 O88573 →
Q5HYW2 — 0.990 Q5HYW2 →
Q6ZQ06 — 0.990 Q6ZQ06 →
Q7TSA6 — 0.989 Q7TSA6 →
Q8IVT2 — 0.989 Q8IVT2 →